Greater Disease Severity and Worse Clinical Outcomes in Patients Hospitalised with COVID-19 in Africa

• Main Authors: Lina Hahnle (Author), Mathilda Mennen (Author), Freedom Gumedze (Author), Daniel Mutithu (Author), Marguerite Adriaanse (Author), Daniel Egan (Author), Simthandile Mazondwa (Author), Rochelle Walters (Author), Lambert Tetteh Appiah (Author), Francisca Inofomoh (Author), Okechukwu Ogah (Author), Olukemi Adekanmbi (Author), Fastone Goma (Author), Elijah Ogola (Author), Kieran Mwazo (Author), Ahmed Suliman (Author), Kavita Singh (Author), Lana Raspail (Author), Dorairaj Prabhakaran (Author), Pablo Perel (Author), Karen Sliwa (Author), Ntobeko A. B. Ntusi (Author)
• Format: Book
• Published: Ubiquity Press, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2211-8179; 10.5334/gh.1314
• Keywords: covid-19; africa; sub-saharan africa; mortality; cardiovascular disease; Diseases of the circulatory (Cardiovascular) system; RC666-701; Public aspects of medicine; RA1-1270
• Source: Global Heart, Vol 19, Iss 1, Pp 34-34 (2024)

Background: COVID-19 cardiovascular research from Africa is limited. This study describes cardiovascular risk factors, manifestations, and outcomes of patients hospitalised with COVID-19 in the African region, with an overarching goal to investigate whether important differences exist between African and other populations, which may inform health policies. Methods: A multinational prospective cohort study was conducted on adults hospitalised with confirmed COVID-19, consecutively admitted to 40 hospitals across 23 countries, 6 of which were African countries. Of the 5,313 participants enrolled globally, 948 were from African sites (n = 9). Data on demographics, pre-existing conditions, clinical outcomes in hospital (major adverse cardiovascular events (MACE), renal failure, neurological events, pulmonary outcomes, and death), 30-day vitality status and re-hospitalization were assessed, comparing African to non-African participants. Results: Access to specialist care at African sites was significantly lower than the global average (71% vs. 95%), as were ICU admissions (19.4% vs. 34.0%) and COVID-19 vaccination rates (0.6% vs. 7.4%). The African cohort was slightly younger than the non-African cohort (55.0 vs. 57.5 years), with higher rates of hypertension (48.8% vs. 46.9%), HIV (5.9% vs. 0.3%), and Tuberculosis (3.6% vs. 0.3%). In African sites, a higher proportion of patients suffered cardiac arrest (7.5% vs. 5.1%) and acute kidney injury (12.7% vs. 7.2%), with acute kidney injury (AKI) appearing to be one of the strongest predictors of MACE and death in African populations compared to other populations. The overall mortality rate was significantly higher among African participants (18.2% vs. 14.2%). Conclusions: Overall, hospitalised African patients with COVID-19 had a higher mortality despite a lower mean age, contradicting literature that had previously reported a lower mortality attributed to COVID-19 in Africa. African sites had lower COVID-19 vaccination rates and higher AKI rates, which were positively associated with increased mortality. In conclusion, African patients were hospitalized with more severe COVID-19 cases and had poorer outcomes.